版本:
中国

BRIEF-GlaxoSmithKline announces positive results from two phase III studies of Tafenoquine​

June 12 GlaxoSmithKline Plc

* ‍GSK and Medicines for Malaria Venture announced positive results from two phase III studies of Tafenoquine​

* Tafenoquine is an investigational 8-aminoquinoline, for prevention of relapse of plasmodium vivax (p.vivax) malaria​

* Headline results show single-dose of 300mg tafenoquine reduced risk of relapse in patients with p.vivax malaria​

* ‍Study met its primary endpoint

* ‍study showed that a statistically significant greater proportion of patients treated with tafenoquine (60%) remained relapse-free over 6-month follow-up period​

* ‍GSK plans to progress regulatory filings for prevention of relapse of p. Vivax malaria later in 2017​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐